NCT00423826: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease |
|
|
| No Longer Available | N/A | | US | Busulfan, Busulfex®, Myleran®, Cytarabine, DepoCyt(TM), Liposomal Ara-C, Fludarabine phosphate, Fludara, mycophenolate mofetil, Cellcept, tacrolimus, Advagraf, Prograf, Protopic, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI) | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis | 01/15 | 01/15 | | |
EAP, NCT00720603: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. |
|
|
| No Longer Available | N/A | | US | Plerixafor, AMD3100, Mozobil | Genzyme, a Sanofi Company | Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma | | | | |
NCT00799539: A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients |
|
|
| No Longer Available | N/A | | Canada | bortezomib, melphalan, prednisone | Janssen-Ortho Inc., Canada, Ortho Biotech Canada | Multiple Myeloma | | | | |
CoMMpass, NCT01454297: Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile |
|
|
| Completed | N/A | 1154 | Europe, Canada, US | | Multiple Myeloma Research Foundation, Translational Genomics Research Institute, Spectrum Health Hospitals, Van Andel Research Institute | Multiple Myeloma | 11/23 | 12/23 | | |